GERN

Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening

Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS IMerge Phase 3 enrollment completion expected in second quarter of 2021 Top-line results expected in

Shares of Geron (NASDAQ:GERN) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share increased 25.00% over the past year to ($0.06), which were in line with the estimate of ($0.06).Revenue of $108,000 decreased by 17.56% year over year, which beat the estimate of $40,000.Guidance Geron hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: Nov 05, 2020View more earnings on GERNTime: 04:30 PMET Webcast URL: http://www.directeventreg.com/registration/event/7879966Recent Stock Performance 52-week high: $2.40Company's 52-week low was at $0.75Price action over last quarter: Up 10.71%Company Description Geron Corp is a clinical stage biopharmaceutical company focused on research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses the global rights to this drug.See more from Benzinga * Click here for options trades from Benzinga * Recap: Trade Desk Q3 Earnings * 12 Technology Stocks Moving In Thursday's Intraday Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Results support ongoing IMerge Phase 3 clinical trial Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published in